LipidSeq: A next-generation clinical resequencing panel for monogenic dyslipidemias

Journal of Lipid Research

Volumn 55, Issue 4, 2014, Pages 765-772

  Johansen, Christopher T ^a   Dubé, Joseph B ^a   Loyzer, Melissa N ^a   MacDonald, Austin ^a   Carter, David E ^a   McIntyre, Adam D ^a   Cao, Henian ^a   Wang, Jian ^a   Robinson, John F ^a   Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

DNA diagnosis; Familial dyslipidemia; Genetic risk score; Mutations; Next generation sequencing; Polygenic dyslipidemia; Sanger sequencing

Indexed keywords

APOA5 GENE; APOB GENE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; DYSLIPIDEMIA; GENE; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GPIHBP1 GENE; HUMAN; INTERMETHOD COMPARISON; LDLR GENE; LIPIDSEQ; LMF1 GENE; LPL GENE; MAJOR CLINICAL STUDY; MODY GENE; MOLECULAR DIAGNOSIS; MONOGENIC DYSLIPIDEMIA; PCSK9 GENE; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

DNA MUTATIONAL ANALYSIS; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR SEQUENCE ANNOTATION; MUTATION;

EID: 84897417989     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D045963     Document Type: Article

References (33)

1. Grada, A., and K. Weinbrecht. 2013. Next-generation sequencing: methodology and application. J. Invest. Dermatol. 133: e11.
2. Metzker, M. L. 2010. Sequencing technologies-the next generation. Nat. Rev. Genet. 11: 31-46.
3. Chang, F., and M. M. Li. Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genet. Epub ahead of print. October 11, 2013; doi;10.1016/j.cancergen.2013.10.003.
4. Sikkema-Raddatz, B., L. F. Johansson, E. N. de Boer, R. Almomani, L. G. Boven, M. P. van den Berg, K. Y. van Spaendonck-Zwarts, J. P. van Tintelen, R. H. Sijmons, J. D. Jongbloed, et al. 2013. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum. Mutat. 34: 1035-1042.
5. Yang, Y., D. M. Muzny, J. G. Reid, M. N. Bainbridge, A. Willis, P. A. Ward, A. Braxton, J. Beuten, F. Xia, Z. Niu, et al. 2013. Clinical wholeexome sequencing for the diagnosis of mendelian disorders. N. Engl. J. Med. 369: 1502-1511.
6. Katsanis, S. H., and N. Katsanis. 2013. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 14: 415-426.
7. Collins, F. S., and M. A. Hamburg. 2013. First FDA authorization for next-generation sequencer. N. Engl. J. Med. 369: 2369-2371.
8. Panoutsopoulou, K., I. Tachmazidou, and E. Zeggini. 2013. In search of low-frequency and rare variants affecting complex traits. Hum. Mol. Genet. 22: R16-R21.
9. Kilpinen, H., and J. C. Barrett. 2013. How next-generation sequencing is transforming complex disease genetics. Trends Genet. 29: 23-30.
10. Heath, K. E., S. E. Humphries, H. Middleton-Price, and M. Boxer. 2001. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur. J. Hum. Genet. 9: 244-252.
11. Fouchier, S. W., J. C. Defesche, M. W. Umans-Eckenhausen, and J. P. Kastelein. 2001. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum. Genet. 109: 602-615.
12. Rahalkar, A. R., F. Giffen, B. Har, J. Ho, K. M. Morrison, J. Hill, J. Wang, R. A. Hegele, and T. Joy. 2009. Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can. J. Physiol. Pharmacol. 87: 151-160.
13. Johansen, C. T., and R. A. Hegele. 2011. Genetic bases of hypertriglyceridemic phenotypes. Curr. Opin. Lipidol. 22: 247-253.
14. Fu, J., S. Kwok, L. Sinai, O. Abdel-Razek, J. Babula, D. Chen, E. Farago, N. Fernandopulle, S. Leith, M. Loyzer, et al. 2013. Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias. Can. J. Cardiol. 29: 934-939.
15. Hegele, R. A., T. R. Joy, S. A. Al-Attar, and B. K. Rutt. 2007. Lipodystrophies: windows on adipose biology and metabolism. J. Lipid Res. 48: 1433-1444.
16. Vigouroux, C., M. Caron-Debarle, C. Le Dour, J. Magre, and J. Capeau. 2011. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int. J. Biochem. Cell Biol. 43: 862-876.
17. Hattersley, A., J. Bruining, J. Shield, P. Njolstad, and K. C. Donaghue. 2009. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes. 10 (Suppl 12) : 33-42.
18. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466: 707-713.
19. Meyer, L. R., A. S. Zweig, A. S. Hinrichs, D. Karolchik, R. M. Kuhn, M. Wong, C. A. Sloan, K. R. Rosenbloom, G. Roe, B. Rhead, et al. 2013. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res. 41: D64-D69.
20. Johansen, C. T., J. Wang, M. B. Lanktree, H. Cao, A. D. McIntyre, M. R. Ban, R. A. Martins, B. A. Kennedy, R. G. Hassell, M. E. Visser, et al. 2010. Excess of rare variants in genes identified by genomewide association study of hypertriglyceridemia. Nat. Genet. 42: 684-687.
21. Johansen, C. T., J. Wang, A. D. McIntyre, R. A. Martins, M. R. Ban, M. B. Lanktree, M. W. Huff, M. Peterfy, M. Mehrabian, A. J. Lusis, et al. 2012. Excess of rare variants in non-genomewide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet. 5: 66-72.
22. Wang, K., M. Li, and H. Hakonarson. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38: e164.
23. Hegele, R. A. 2009. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10: 109-121.
24. Calandra, S., P. Tarugi, H. E. Speedy, A. F. Dean, S. Bertolini, and C. C. Shoulders. 2011. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J. Lipid Res. 52: 1885-1926.
25. Talmud, P. J., S. Shah, R. Whittall, M. Futema, P. Howard, J. A. Cooper, S. C. Harrison, K. Li, F. Drenos, F. Karpe, et al. 2013. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a casecontrol study. Lancet. 381: 1293-1301.
26. Musunuru, K., J. P. Pirruccello, R. Do, G. M. Peloso, C. Guiducci, C. Sougnez, K. V. Garimella, S. Fisher, J. Abreu, A. J. Barry, et al. 2010. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363: 2220-2227.
27. Marduel, M., K. Ouguerram, V. Serre, D. Bonnefont-Rousselot, A. Marques-Pinheiro, K. Erik Berge, M. Devillers, G. Luc, J. M. Lecerf, L. Tosolini, et al. 2013. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum. Mutat. 34: 83-87.
28. Stitziel, N. O., S. W. Fouchier, B. Sjouke, G. M. Peloso, A. M. Moscoso, P. L. Auer, A. Goel, B. Gigante, T. A. Barnes, O. Melander, et al. 2013. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33: 2909-2914.
29. Koboldt, D. C., D. E. Larson, K. Chen, L. Ding, and R. K. Wilson. 2012. Massively parallel sequencing approaches for characterization of structural variation. Methods Mol. Biol. 838: 369-384.
30. Biesecker, L. G. 2012. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet. Med. 14: 393-398.
31. Biesecker, L. G., W. Burke, I. Kohane, S. E. Plon, and R. Zimmern. 2012. Next-generation sequencing in the clinic: are we ready? Nat. Rev. Genet. 13: 818-824.
32. Gonzalez-Garay, M. L., A. L. McGuire, S. Pereira, and C. T. Caskey. 2013. Personalized genomic disease risk of volunteers. Proc. Natl. Acad. Sci. USA. 110: 16957-16962.
33. Green, R. C., J. S. Berg, W. W. Grody, S. S. Kalia, B. R. Korf, C. L. Martin, A. L. McGuire, R. L. Nussbaum, J. M. O'Daniel, K. E. Ormond, et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15: 565-574.